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ABSTRACT
Background: In May 2007 Nissen and Wolski reported the results of a meta-analysis showing an association be-
tween use of rosiglitazone and increased risk of myocardial infarction (N Engl J Med 2007;356[24]:2457–2471). Rosi-
glitazone is an insulin-sensitizing agent used to control blood glucose levels in patients with type 2 diabetes. Subse-
quent analyses provided evidence that the meta-analysis led to a decline in new and prevalent use of rosiglitazone. 
We sought to evaluate the impact of the meta-analysis on patterns of use of glucose-lowering drugs and patterns of 
initiation, cessation and switching of drug therapy, and to estimate the impact in relation to other predictors of initia-
tion and cessation of rosiglitazone.
Methods: We used an interrupted time series analysis to test the impact of the meta-analysis on monthly utilization 
of glucose-lowering drugs for the 4.3 million residents of the province of British Columbia. We used multivariate lo-
gistic regression with generalized estimating equations to test predictors of initiation and cessation of rosiglitazone, 
including the influence of microvascular and macrovascular comorbidities, before and after the meta-analysis. 
Results: A comparison of predicted and observed utilization for November 2007 showed that use of rosiglitazone de-
clined by 40% (95% confidence interval 39%–42%), whereas use of pioglitazone, insulin and sulfonylureas increased. 
The presence of macrovascular comorbidities strengthened both the negative impact of the meta-analysis on initiation 
of rosiglitazone therapy and the positive impact of the meta-analysis on cessation of this drug. 
Interpretation: The shift in utilization from rosiglitazone to insulin and sulfonylureas and the modest increase in 
use of pioglitazone suggest that the latter drug was not embraced as a less harmful alternative to rosiglitazone. Macro-
vascular comorbidities played a greater role in decisions to start or stop rosiglitazone therapy after the meta-analysis 
was published. 
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I
n  a  meta-analysis  published  in  late  may  2007, 
Nissen  and  Wolski  showed  that  rosiglitazone  was 
associated with a higher rate of myocardial infarc-
tion  than  placebo  or  other  glucose-lowering  medica-
tions.1  The  US  Food  and  Drug  Administration  (FDA) 
issued a related safety alert on the same day the article 
was  published.2  On  1  June  2007  a  letter  highlighting 
these harmful effects, issued by GlaxoSmithKline and 
reviewed by Health Canada, was sent to health profes-
sionals in Canada.3 Rosiglitazone (Avandia) is 1 of 2 thia-
zolidinediones (TZDs) currently on the market in North 
America; the other is pioglitazone (Actos). Combination 
products include rosiglitazone–metformin, marketed as 
Avandamet. Recently published findings have indicated 
that rosiglitazone use has declined sharply since the re-
lease of the Nissen and Wolski findings.4–6 More specif-
ically, an analysis of elderly patients in Ontario showed 
that new use of rosiglitazone dropped abruptly following 
publication of the meta-analysis,4 and a drug utilization 
study in a private insurance plan setting indicated that 
prevalent use of rosiglitazone by members of the plan fell 
by close to half from 20 May to 7 Dec. 2007.5 The latter 
study also revealed that the percentage of rosiglitazone 
users with an elevated risk for a cardiovascular event de-
clined during the same period. These studies have pro-
vided evidence that the meta-analysis affected the use 
of TZDs, but, importantly, they did not analyze patterns 
of switching from rosiglitazone to other drugs, nor did 
they consider the wider effects on prevalent use of other 
glucose-lowering medications. 
We therefore undertook a study to examine the wider 
effects of the Nissen and Wolski meta-analysis, includ-
ing its impact on patterns of prevalent and new use of 
glucose-lowering  medications,  cessation  of  TZDs,  and 
switching from rosiglitazone to other medications. We 
also sought to identify predictors of initiation and ces-
sation  of  rosiglitazone,  including  microvascular  and 
macrovascular comorbidities. In this article, we describe 
the impact of the meta-analysis on use of glucose-lower-
ing drugs and provide an analysis of the factors influen-
cing utilization of rosiglitazone over time.
Methods
Study population. For this study, we focused on drug 
utilization in the Canadian province of British Colum-
bia. TZDs were covered by the provincial drug plan as 
third-line  therapies  under  a  prior-authorization  pro-
cess as of 7 Nov. 2005 for rosiglitazone and pioglitazone 
and as of 2 Aug. 2007 for the combination drug rosig-
litazone–metformin.7, 8  Before  these  coverage  policies 
were implemented, TZDs had been available but had not 
been covered by the public drug plan. 
We  used  linked  data  from  provincial  administrative 
health databases for prescription drugs (PharmaNet), phys-
ician services (Medical Services Plan) and hospital admis-
sions (Canadian Institute for Health Information Discharge 
Abstracts  Database).  PharmaNet  contains  records  of  all 
medications dispensed at community pharmacies in British 
Columbia, and rates of underreporting and misclassification 
were expected to be minimal.9 Similarly, physician services 
and hospital admissions data were expected to be reliable on 
the basis of studies comparing patient charts with adminis-
trative data in Canada.10,   11 Our study included B.C. residents 
of any age (about 4.3 million people in 2007). We restricted 
the sample to those registered under the Medical Services 
Plan to ensure exclusion of non-residents. In our analysis of 
predictors of initiation and cessation of rosiglitazone, we fur-
ther limited the sample to those registered in the provincial 
income-based prescription drug plan (Fair PharmaCare) to 
ensure that we had detailed data on income for all study par-
ticipants. The study covered the 36-month period from De-
cember 2004 to November 2007, which consisted of the 29 
months before the Nissen and Wolski meta-analysis of rosig-
litazone was published,1 a transition month during which the 
study was published online (May 2007) and the 6 months 
after publication. 
Definitions. Patients with 1 or more days’ supply of a 
drug within a given month were considered “prevalent 
users” of the drug during that month. Patients whose 
current supply of a drug was set to expire during a given 
month and who did not fill another prescription for the 
same drug within 90 days of the end of their current 
supply  were  defined  as  having  stopped  the  drug.9,12–14 
Patients for whom a drug was dispensed in the current 
month and for whom the drug had not been dispensed in 
the previous 365 days were defined as having started the 
drug. Patients for whom a new glucose-lowering therapy 
was dispensed within 30 days of stopping rosiglitazone 
or  rosiglitazone–metformin  were  defined  as  having 
switched therapies.12–14
Interrupted time series analysis. We used an inter-
rupted time series linear regression model15, 16 to test for 
changes in monthly prevalent use, treatment initiation 
and treatment cessation of rosiglitazone, rosiglitazone–
metformin, pioglitazone, all TZDs, insulin, metformin, 
sulfonylureas, acarbose and repaglinide. We also used 
this model to test for changes in monthly switching from 
rosiglitazone  or  rosiglitazone–metformin  to  the  other Open Medicine 2010;4(1):e52
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glucose-lowering medications included in the study. The 
model included an intercept, a linear trend variable, a bi-
nary variable for the transition month during which the 
meta-analysis  was  published  online  (May  2007),  level 
and trend variables for the period after the meta-analy-
sis (June–November 2007), level and trend variables for 
the period after the prior-authorization policy for TZDs 
was  introduced  (November  2005  to  November  2007), 
and monthly variables to control for seasonal variation. 
Although  the  same  independent  variables  were  used, 
separate regressions were estimated for prevalent use, 
treatment initiation, treatment cessation and switching 
and for each drug in the study. This model was also used 
to estimate, on the basis of trends in prevalent use before 
the meta-analysis was published, the “predicted” num-
ber of prevalent users of each glucose-lowering drug in 
the absence of the meta-analysis; these values allowed 
comparison with observed prevalence figures for Nov-
ember 2007. For more detail about the interrupted time 
series model, see the Appendix (online). We used SAS 
version 9.1 (SAS Institute, Inc., Cary, N.C.) for this and 
all other statistical analyses.
Predictors of initiation and cessation of rosig-
litazone. We tested factors that have been hypothesized 
to  predict  initiation  of  rosiglitazone  or  rosiglitazone–
metformin among patients with diabetes mellitus or to 
predict cessation of rosiglitazone or rosiglitazone–met-
formin among patients with a current prescription for 
these drugs. We used separate logistic regressions to es-
timate the influence of these factors on initiation and on 
cessation of rosiglitazone or rosiglitazone–metformin.9, 13 
The  method  of  generalized  estimating  equations  was 
used to adjust for correlations within participants across 
repeated observations.17–20 
The logistic regression model included a term for a 
linear  time  trend,  binary  variables  for  the  transition 
period (May 2007) and the period following the meta-
analysis (June–November 2007), and a binary variable 
for the period of B.C. PharmaCare coverage for TZDs 
under a prior authorization policy (November 2005 to 
November  2007).  Binary  variables  were  included  for 
several of the patients’ characteristics, specifically sex, 
age category, income level, Romano comorbidity score, 
presence  of  comorbidities  (macrovascular  or  micro-
vascular comorbidities or hypertension) and insulin de-
pendence (defined as 2 or more prescriptions for insulin 
in the previous 6 months). The Romano comorbidity 
score is an index of a patient’s comorbidities based on 
previous diagnoses the patient has received, and this 
was included as a variable to adjust for confounding 
caused  by  comorbidities,9,21,22  excluding  diabetes  (a 
diagnosis assumed to be shared by all persons in the 
initiation  and  cessation  analyses).  The  binary  vari-
ables for the presence of macrovascular comorbidities, 
microvascular comorbidities and hypertension (coded 
as shown in Table 1)23–25 were based on whether the pa-
tient had received a diagnosis in one of these categor-
ies during a physician or hospital visit in the previous 
365 days. We also created interaction terms by multi-
plying each of the binary variables for macrovascular 
and  microvascular  comorbidities  and  hypertension 
with the binary variable for the period following the 
meta-analysis, to test whether the effect of these fac-
tors changed during the period after the meta-analysis 
was published. 
Table 1: Diagnostic codes for comorbidities in analysis of predictors of rosiglitazone initiation and cessation
Comorbidity Complex care codes* ICD-9 codes ICD-10 codes
Macrovascular
    Angina NA 411, 413 I20
    Cerebrovascular disease NA 430–438 I60–I69
    Congestive heart failure H250 424–428 I50
    Myocardial infarction NA 410, 412 I21,122
    Other ischemic heart disease I250 414 I24, I25
    Peripheral vascular disease NA 443 I73
Microvascular
    Acute renal disease V451 403, 404, 584, 586 N17
    Chronic renal disease D585 582, 583, 585–587, 589 N18
    Diabetic neuropathy NA 205.6, 337, 357 E10.4, E11.4, E12.4, E13.4, E14.4
    Retinal disorder NA 362 E10.3, E11.3, E12.3, E13.3, E14.3, H35, H36
Hypertension NA 401–405 I10–I13, I15
ICD-9 = International Classification of Disease, 9th revision; ICD-10 = International Classification of Diseases, 10th revision; NA = not available.
*Created by the BC Ministry of Health Services to specify comorbidities that occur in association with diabetes mellitus.Open Medicine 2010;4(1):e53
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Using  the  logistic  regression  model,  we  calculated 
odds ratios (ORs) and confidence intervals (CIs) to es-
timate  the  influence  of  each  of  the  variables  in  the 
model on initiation and cessation of rosiglitazone and 
rosiglitazone–metformin.  From  the  interaction  terms 
described above (for macrovascular, microvascular and 
hypertension comorbidity variables), we calculated ORs 
and CIs to represent the impact of the meta-analysis in 
the absence and presence of each of these comorbidities 
and to represent the impact of these comorbidities before 
and after the meta-analysis. For more detail on the logis-
tic regression model with generalized estimating equa-
tions, see the Appendix (online).
Results
Utilization trends for glucose-lowering medi-
cations.  The  introduction,  in  November  2005,  of 
public  coverage  for  rosiglitazone  and  pioglitazone 
under  a  prior-authorization  policy  was  associated 
with  a  modest  increase  in  overall  TZD  utilization, 
although it had a negative effect on the use of rosi-
glitazone–metformin  (which  was  not  publicly  cov-
ered until August 2007) (Fig. 1). After the Nissen and 
Wolski meta-analysis was published in May 2007, the 
number of prevalent users of rosiglitazone and rosi-
glitazone–metformin  declined.  This  trend  coincided 
with a more modest increase in the number of piog-
litazone users, which led to an overall steady decline in 
the prevalence of TZD therapy (Fig. 1). A comparison 
of  predicted  and  observed  utilization  for  November 
2007 (Table 2) showed that rosiglitazone use was 40% 
(95% CI 39%–42%) lower than the predicted level of 
use. At the same time, the observed numbers of users 
of pioglitazone, insulin, sulfonylureas, acarbose and 
repaglinide exceeded the predicted numbers (Table 2). 
In the interrupted time 
series  analysis,  we  found 
that the rate of treatment 
cessation  increased  for 
rosiglitazone  and  rosig-
litazone–metformin,  but 
there  was  no  statistic-
ally  significant  change  in 
treatment  cessation  for 
pioglitazone.  In  the  an-
alysis  of  switching  from 
rosiglitazone  or  rosig-
litazone–metformin  to 
other  glucose-lowering 
drugs,  there  was  a  slight 
increase  in  switching  to  pioglitazone  (1.2%,  95%  CI 
1.1%–1.4%), even smaller increases in switching to other 
medications, and no change in switching to repaglinide. 
Levels of treatment initiation decreased for rosiglitazone 
and  rosiglitazone–metformin  and  increased  for  piog-
litazone, insulin, metformin, sulfonylureas and acarbose 
(data available on request). 
Predictors of initiation and cessation of rosig-
litazone. A total of 305 969 patients were included in 
our analysis of predictors of initiation of rosiglitazone, 
and 17 573 patients were included in the analysis of pre-
dictors of cessation (Table 3). Following publication of 
the meta-analysis in 2007, patients were 75% less like-
ly  to  initiate  rosiglitazone  or  rosiglitazone–metformin 
(OR 0.25, 95% CI 0.21–0.29), and the relative odds of a 
patient stopping such therapy were more than 3 times 
higher (OR 3.29, 95% CI 3.01–3.61) (Table 4). The intro-
duction of public coverage for rosiglitazone (under the 
prior-authorization  policy),  patient  age,  income  level, 
Romano comorbidity score and insulin dependence also 
affected initiation and cessation (Table 4).
The  presence  of  macrovascular  comorbidities  was 
an effect modifier that strengthened both the negative 
impact of the meta-analysis on the level of rosiglitazone 
initiation  (OR  0.18,  95%  CI  0.14–0.24)  and  the  posi-
tive impact on cessation of this drug (OR 3.96, 95% CI 
3.48–4.49) (Table 4). Similarly, the presence of macro-
vascular  comorbidities  was  a  borderline  insignificant 
predictor of rosiglitazone initiation after publication of 
the meta-analysis (OR 0.78, 95% CI 0.59–1.02) and was a 
stronger predictor of treatment cessation (OR 1.36, 95% 
CI 1.24–1.48). The presence of microvascular comorbid-
ities appeared to be a weaker predictor of rosiglitazone 
initiation after publication of the meta-analysis relative 
Table 2: Comparison of observed and predicted prevalence* of glucose-lowering drugs  
in November 2007 (6 months after publication of meta-analysis)
Drug Observed 
Predicted  
estimate (95% CI)
Estimated  
difference
Estimated %  
difference (95% CI)
All TZDs 355 482 (476–487) –127 –26 (–27 to –25)
Rosiglitazone 168 281 (274–289) –113 –40 (–42 to –39)
ROSMET 29 46 (39–53) –17 –37 (–45 to –26)
Pioglitazone 161 153 (148–157) 8 5 (3 to 9)
Insulin  702 685 (681–689) 17 2 (2 to 3)
Metformin 2441 2430 (2410–2450) 11 0.5 (–0.4 to 1)
Sulfonylureas 1178 1159 (1153–1166) 19 2 (1 to 2)
Acarbose 43 39 (37–40) 4 10 (8 to 16)
Repaglinide 41 39 (38–40) 2 5 (2 to 8)
 CI = confidence interval, TZD = thiazolidinedione, ROSMET = rosiglitazone–metformin.
*Observed or predicted number of prevalent users per 100 000 B.C. residents registered in the B.C. Medical Services Plan.Open Medicine 2010;4(1):e54
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to the period before publication (OR 1.31, 95% CI 1.02–
1.69). Also, hypertension became a significant predictor 
of rosiglitazone cessation after publication of the meta-
analysis (OR 1.10, 95% CI 1.02–1.18). 
Interpretation
Publication of the meta-analysis by Nissen and Wolski1 
led to a decline in use of rosiglitazone and a correspond-
ing rise in monthly prevalence of use of other glucose-
lowering  drugs,  including  pioglitazone,  insulin  and 
sulfonylureas. The prevalence of metformin use did not 
change  significantly,  perhaps  because  some  patients 
who were taking metformin and rosiglitazone stopped 
both medications or because some patients experienced 
therapeutic failure with metformin (a common first-line 
therapy) before rosiglitazone was initiated. In our analy-
sis of predictors of rosiglitazone initiation and cessation, 
we found that macrovascular comorbidities had a greater 
impact on decisions not to initiate or to stop rosiglitazone 
therapy after publication of the meta-analysis. The num-
ber of pioglitazone users rose only modestly, while the 
number  of  rosiglitazone  users  steadily  declined.  This 
combination of trends suggests that the increased risk 
of myocardial infarction was not sufficiently interpreted 
as a class effect to reduce the use of pioglitazone, but pio-
glitazone was not embraced as a less harmful alterna-
tive.  The  results  of  an  earlier  utilization  study,  which 
found that the percentage of rosiglitazone users at higher 
cardiovascular risk declined in the latter half of 2007, 
were consistent with our findings.5 Moreover, our find-
ings indicate that this shift in utilization resulted from 
changes in both starting and stopping decisions, which 
the previous study did not measure.
The decline in new and prevalent use of rosiglitazone 
and the rise in pioglitazone use documented in our study 
are  consistent  with  the  results  of  previous  studies4–6 
examining the impact of the meta-analysis by Nissen and 
Wolski, but we have also demonstrated a link between the 
meta-analysis and an increase in prevalent use of insulin 
and sulfonylureas. This shift may have also been related 
to patients “switching back” to drugs they had used at 
some time in the previous 365 days, although our analysis 
would not have counted them as having started the drug 
or as having switched therapies in that case. These results 
differed from a study of Ontario people over age 65, which 
found  no  increased  initiation  of  metformin,  insulin  or 
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Figure 1: Monthly utilization of thiazolidinediones (TZDs) in British Columbia (per 100 000 population) before and after publication 
of a meta-analysis about risks associated with rosiglitazone therapy. The monthly utilization levels plotted are defined as the number of 
users of each medication per 100 000 BC residents registered for medical coverage in the B.C. Medical Services Plan. The dashed vertical line 
on the left indicates the date when public coverage was introduced for rosiglitazone and pioglitazone (7 Nov 2005), and the dashed line 
on the right indicates the online publication of the Nissen and Wolski meta-analysis (21 May 2007). ROS = rosiglitazone, PIO = pioglitazone, 
ROSMET = rosiglitazone–metformin.Open Medicine 2010;4(1):e55
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glibenclamide.4 The Ontario study raised the concern that 
absence of an increase in insulin initiation might indicate 
that patients were not receiving “an appropriate escala-
tion in therapy.”  4 By estimating changes in both new and 
prevalent use of glucose-lowering therapies (for a popula-
tion of all ages), we were able to demonstrate not only that 
TZD use dropped but also that patients used other medi-
cations, including insulin, as alternatives to TZDs.
The Nissen and Wolski meta-analysis1 has been criti-
cized for its statistical methods, and its results cannot be 
considered  definitive.26,27  Nonetheless,  other  meta-an-
alyses,28 including one by the manufacturer,29 have pro-
duced similar findings.30 In October 2008, a consensus 
statement from the American Diabetes Association and 
the European Association for the Study of Diabetes  31, 32 
advised against using rosiglitazone and recommended 
Table 3: Characteristics of patients included in analyses of initiation and cessation of rosiglitazone
Characteristic
Type of analysis; no. (%) of patients
Initiation Cessation
Sex
    Male 153 780 (50.3) 9 995 (56.9)
    Female 152 189 (49.7) 7 578 (43.1)
Age, yr
    < 40 27 738 (9.1) 507 (2.9)
    40–59 96 663 (31.6) 6 809 (38.7)
    60–79 145 827 (47.7) 9 086 (51.7)
    ≥ 80 35 741 (11.7) 1 171 (6.7)
Income, $
    < 25 000 103 288 (33.8) 4 181 (23.8)
    25 000–49 999 92 799 (30.3) 5 281 (30.1)
    50 000–74 999 54 125 (17.7) 3 748 (21.3)
    75 000–99 999 31 696 (10.4) 2 339 (13.3)
    ≥ 100 000 24 061 (7.9) 2 024 (11.5)
Romano score (excluding diabetes)
    0 228 476 (74.7) 13 725 (78.1)
    1 41 812 (13.7) 2 017 (11.5)
    ≥ 2 35 681 (11.7) 1 831 (10.4)
Comorbidities
Macrovascular  50 820 (16.6) 2 845 (16.2)
Angina 23 389 (7.6) 1 375 (7.8)
Cerebrovascular disease 8 054 (2.6) 417 (2.4)
Congestive heart failure  14 309 (4.7) 659 (3.8)
Myocardial infarction 5 651 (1.8) 295 (1.7)
Other ischemic heart disease  17 160 (5.6) 998 (5.7)
Peripheral vascular disease 4 165 (1.4) 236 (1.3)
Microvascular  35 977 (11.8) 3 277 (18.6)
Acute renal disease  7 444 (2.4) 569 (3.2)
Chronic renal disease  7 591 (2.5) 583 (3.3)
Diabetic neuropathy  1 758 (0.6) 180 (1.0)
Retinal disorder  27 507 (9.0) 2 650 (15.1)
Hypertension  126 306 (41.3) 6 576 (37.4)
Insulin dependence
No (< 2 insulin prescriptions in previous 6 mo) 281 225 (91.9) 16 248 (92.5)
Yes (≥ 2 insulin prescriptions in previous 6 mo) 24 744 (8.1) 1 325 (7.5)
Total no. of patients 305 969 (100.0) 17 573 (100.0)
*Data reflect patients' characteristics during the month they entered the study.Open Medicine 2010;4(1):e56
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Table 4: Multivariate analysis of predictors of initiation and cessation of rosiglitazone
Characteristic
Odds ratio (95% confidence interval)
Treatment initiation  
n = 305 969*
Treatment cessation
n = 17 573†
Publication of Nissen and Wolski1 meta-analysis
Impact in absence of measured comorbidities 0.25 (0.21–0.29) 3.29 (3.01–3.61)
Impact in presence of macrovascular comorbidities 0.18 (0.14–0.24) 3.96 (3.48–4.49)
Impact in presence of microvascular comorbidities 0.21 (0.16–0.27) 3.34 (2.96–3.76)
Impact in presence of hypertension 0.24 (0.20–0.29) 3.66 (3.30–4.07)
Impact during transition period (May 2007) 0.72 (0.62–0.83) 1.88 (1.66–2.14)
Introduction of coverage of TZDs (under prior-authorization policy) 1.12 (1.03–1.22) 1.28 (1.17–1.40)
Sex
Male 1.00 1.00
Female 0.86 (0.83–0.90) 1.02 (0.97–1.07)
Age, yr
< 40 1.00 1.00
40–59 2.73 (2.41–3.08) 0.63 (0.54–0.73)
60–79 2.21 (1.95–2.50) 0.60 (0.52–0.70)
≥ 80 1.30 (1.13–1.50) 0.49 (0.42–0.59)
Income, $
< 25 000 1.00 1.00
25 000–49 999 1.05 (1.00–1.11) 0.74 (0.70–0.79)
50 000–74 999 1.13 (1.07–1.20) 0.65 (0.61–0.70)
75 000–99 999 1.20 (1.12–1.29) 0.64 (0.60–0.70)
≥ 100 000 1.21 (1.12–1.30) 0.64 (0.59–0.69)
Romano score (excluding diabetes)
0 1.00 1.00
1 0.81 (0.76–0.87) 1.06 (1.00–1.14)
≥ 2 0.77 (0.72–0.83) 1.09 (1.01–1.17)
Comorbidities
Macrovascular
Before publication of meta-analysis 1.06 (0.99–1.12) 1.13 (1.05–1.21)
After publication of meta-analysis 0.78 (0.59–1.02) 1.36 (1.24–1.48)
Microvascular
Before publication of meta-analysis 1.56 (1.47–1.65) 1.00 (0.94–1.07)
After publication of meta-analysis 1.31 (1.02–1.69) 1.01 (0.93–1.10)
Hypertension
Before publication of meta-analysis 0.83 (0.79–0.86) 0.99 (0.94–1.04)
After publication of meta-analysis 0.80 (0.66–0.96) 1.10 (1.02–1.18)
Insulin dependence
No (< 2 insulin prescriptions in previous 6 mo) 1.00 1.00
Yes (≥ 2 insulin prescriptions in previous 6 mo) 0.46 (0.42–0.50) 1.35 (1.25–1.45)
Note: This analysis tested initiation and cessation of treatment with rosiglitazone and rosiglitazone–metformin.
* There were 305 969 unique patients and 7 667 891 observations, with multiple observations for patients included in more than 1 monthly panel.
† There were 17 573 unique patients and 146 396 observations, with multiple observations for patients included in more than 1 monthly panel.Open Medicine 2010;4(1):e57
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pioglitazone as only a third-line therapy, on the basis 
of  existing  evidence.  More  recently,  the  randomized, 
open-label RECORD trial compared rosiglitazone com-
bination therapy with therapy consisting of metformin 
and a sulfonylurea.33 That study was designed to inves-
tigate  cardiovascular  outcomes  for  these  combination 
therapies,  and  the  non-inferiority  criterion  was  met 
for the trial’s primary outcome of admission to hospi-
tal for cardiovascular reasons or cardiovascular death. 
The study showed no significant difference between the 
rosiglitazone and comparator groups for the predefined 
secondary composite outcome of cardiovascular death, 
myocardial infarction and stroke, but rosiglitazone use 
was associated with increased risk of heart failure and 
bone fractures. Critics of the study have suggested that 
the choice of primary outcome and the low event rates 
in  the  trial  are  weaknesses  and  therefore  that  strong 
conclusions cannot be drawn from the results.34,35 Two 
recent observational studies suggested that pioglitazone 
may be a safer choice than rosiglitazone.36, 37 Neither of 
these  observational  studies  reported  a  significant  dif-
ference in risk for myocardial infarction between rosi-
glitazone and pioglitazone, but both reported increased 
risk  for  all-cause  mortality  and  for  heart  failure  with 
rosiglitazone. 
Other safety information may have contributed to the 
decline in overall TZD utilization or, more specifically, to 
caution in the use of pioglitazone, including warnings in 
early 2007 in both Canada and the United States about 
risk of fracture,38–41 FDA boxed warnings related to heart 
failure in August 2007  42 and a Health Canada endorsed 
advisory about rosiglitazone and cardiac safety in Nov-
ember 2007.43 A limitation of our study was the inability 
to separately measure the effects of each warning. In our 
analysis of predictors of initiation and cessation of rosi-
glitazone, the influence of macrovascular comorbidities 
on utilization of this drug may have been due in part to 
an increase in concerns about congestive heart failure 
rather than only a response to the findings of Nissen and 
Wolski.1 However, we can infer from the rise in the num-
ber of pioglitazone users that the decline in rosiglitazone 
use resulted primarily from the publication of the meta-
analysis and related regulatory warnings and publicity. 
Our study shares a limitation with other studies of this 
kind in that longer-term data would be needed to show 
the long-term impact of the meta-analysis, although in 
interrupted time series analysis it becomes more diffi-
cult to attribute changes to a previous event or interven-
tion over a longer timeframe because of other changes at 
the patient or population level (such as additional safety 
information).14 As noted above, we probably underesti-
mated  the  amount  of  switching  from  rosiglitazone  or 
rosiglitazone–metformin  to  other  glucose-lowering 
drugs, since our definition of switching did not count pa-
tients who “switched back” to a drug they had used in 
the past 365 days. However, changes in switching would 
be  captured  in  our  analysis  of  prevalent  use  of  these 
medications. Similarly, we did not measure the number 
of patients who increased the dosage of a current medi-
cation to compensate for stopping rosiglitazone or rosig-
litazone–metformin. Although we were able to report on 
the impact of the meta-analysis on trends in utilization 
and the modifying effect of macrovascular comorbidities 
on rosiglitazone utilization after publication of the meta-
analysis, we did not evaluate the effects of these shifts in 
utilization on patients’ health outcomes and cannot draw 
conclusions about such effects.
We found that publication of the Nissen and Wolski 
meta-analysis of rosiglitazone in May 2007 led to a de-
cline in the prevalence of use of rosiglitazone and a shift 
toward  greater  use  of  pioglitazone  and  other  glucose-
lowering  drugs,  including  insulin  and  sulfonylureas. 
Use  of  rosiglitazone  therapy  was  influenced  by  a  var-
iety  of  factors,  including  demographic  characteristics 
and health indicators. Our results provide evidence that 
macrovascular comorbidities played a greater role in de-
cisions to start or stop rosiglitazone therapy as a result 
of the meta-analysis. Although other warnings about the 
safety of TZDs were issued in 2007, the findings pub-
lished by Nissen and Wolski appeared to be more influ-
ential, which may relate to broader coverage in the lay 
and professional media4–6 or to the perceived severity 
of risk of myocardial infarction relative to other safety 
concerns.
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